Ohio is currently home to 3228 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
NCT06824467
Recruiting
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and If people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Cincinnati Medical Center ( Site 0090), Cincinnati, Ohio
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Register for Updates
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT06685835
Recruiting
The primary purpose of the study is evaluate the effect of brensocatib compared with placebo.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/06/2025
Locations: USA016, Springfield, Ohio
Conditions: Hidradenitis Suppurativa
Register for Updates
Open-Label Extension of EryDex Study IEDAT-04-2022
NCT06664853
Recruiting
This is an international, multi-center, prospective, open-label, non-comparative study to provide EryDex treatment to ataxia telangiectasia (A-T) patients who complete the IEDAT-04-2022 trial on the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
Gender:
ALL
Ages:
6 years and above
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital, Division of neurology, Cincinnati, Ohio
Conditions: Ataxia Telangiectasia
Register for Updates
Addiction Potential of Very Low Nicotine Filtered Little Cigars
NCT06630728
Recruiting
The goal of this clinical trial is to learn how reducing the nicotine content in filtered little cigars can affect the the use of these cigars and lung health in current adult filtered little cigar users. The main question\[s\] it aims to answer are: Are puffing behaviors, appeal/satisfaction, craving suppression, pharmacokinetic effects, and demand similar between the regular cigars smoked by participants, normal nicotine study cigars and very low nicotine study cigars? Are health effects and... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
06/06/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Smoking (Tobacco) Addiction
Register for Updates
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
NCT06627647
Recruiting
The purpose of ARTEMIDE-Lung03 is to evaluate the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line treatment of patients with non-squamous mNSCLC whose tumors express PD-L1.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Research Site, Canton, Ohio
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1
NCT06541847
Recruiting
The trial will be an open label, single arm, phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
06/06/2025
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Neurofibromatosis Type 1
Register for Updates
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704
Recruiting
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have geographic atrophy (GA) caused by age-related macular degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/06/2025
Locations: Cincinnati Eye Institute, Cincinnati, Ohio
Conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Register for Updates
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
NCT06520345
Recruiting
The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University Hospital, Cleveland, Ohio
Conditions: Metastatic Castration-resistant Prostate Cancer
Register for Updates
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Miami Valley Hospital South, Centerville, Ohio
Conditions: Breast Cancer
Register for Updates
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277
Recruiting
Researchers are looking for a better way to treat people who have advanced non-small cell lung cancer (NSCLC) with specific genetic changes called human epidermal growth factor receptor 2 (HER2) mutations. Advanced NSCLC is a group of lung cancers that have spread to nearby tissues or to other parts of the body or that are unlikely to be cured or controlled with currently available treatments. HER2 is a protein that helps cells to grow and divide. A damage (also called mutation) to the building... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Advanced Non-small Cell Lung Cancer, HER2 Mutation
Register for Updates
Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia
NCT06449378
Recruiting
The purpose of RECOVER is to evaluate the performance and safety of Transorb™ self-gripping resorbable mesh in high-risk subjects (at least one risk factor impairing wound healing) when used for reinforcement of abdominal wall soft tissues in procedures involving open extraperitoneal ventral hernia repair, in clean (US); and clean and clean-contaminated (Europe) surgical fields (Centers for Disease Control and Prevention (CDC) Classification I and II. Data from this study will primarily be used... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Hernia, Hernia, Ventral, Hernia, Abdominal, Hernia Abdominal Wall
Register for Updates
PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm
NCT06445608
Recruiting
This purpose of this trial is to demonstrate 30 day safety and effectiveness outcomes of the KARDION CORY P4 System in subjects who require hemodynamic support during a high-risk PCI procedure.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
06/06/2025
Locations: The Lindner Research Center at The Christ Hospital, Cincinnati, Ohio
Conditions: Coronary Artery Disease
Register for Updates